Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

Bousser, M G;Amarenco, P;Chamorro, A;Fisher, M;Laloux, Patrice;et.al.
(2009) Cerebrovascular Diseases — Vol. 27, n° 5, p. 509-518 (2009)

Files

BousserMG-CerebrovascDis-2009.pdf
  • Restricted Access
  • Adobe PDF
  • 187.53 KB
Request a copy

Details

Authors
  • Bousser, M G
    Author
  • Amarenco, P
    Author
  • Chamorro, A
    Author
  • Fisher, M
    Author
  • Peeters, AndréUCLouvain
    Collaborator
  • Laloux, PatriceUCLouvain
    Collaborator
Show more
Abstract
The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bousser, M. G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K., Hennerici, M. G., Mattle, H. P., & Rothwell, P. M. (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular Diseases, 27(5), 509-518. https://doi.org/10.1159/000212671 (Original work published 2009)